Parse Biosciences, the leader in accessible and scalable single cell sequencing, today affirmed their plans to proceed with development and future ...

Parse Biosciences affirms plans to proceed with development and future release of their Evercode™ single cell chromatin ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 11,320,000 ...

Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with ...

Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.

Recovery from oversold momentum indicator, the upcoming Pectra upgrade and Wednesday's CPI report are among the catalysts that could fuel an ETH rally,, a 10x Research report noted.

As the second day of AGBT came to a close, Julianna LeMieux, PhD, Deputy Editor in Chief at GEN, chatted with Kevin Davies, PhD, GEN ‘s Editorial Director, about some of the biggest announcements from ...

At the Advances in Genome Biology and Technology, AGBT, General Meeting, 10x Genomics (TXG) announced a series of new product innovations to ...

Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...